SC
ADCT icon

Stempoint Capital’s ADC Therapeutics ADCT Stock Holding History

Stempoint Capital’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-502,570
Closed -$1.77M – 86
2025
Q4 		$1.77M Buy
502,570
+219,284
+77% +$890K 0.3% 59
2025
Q3 		$1.13M Hold
283,286
– – 0.23% 61
2025
Q2 		$759K Buy
+283,286
New +$596K 0.24% 47

Other funds holding ADCT

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Stempoint Capital's ADCT Position: Q1 2026 in Review

Stempoint Capital sold out of ADC Therapeutics (ADCT) in Q1 2026, closing a stake of 502,570 shares — an estimated $1.77M sold.

Stempoint Capital first reported a position in ADCT in Q2 2025 and held it in 3 quarters. The position peaked at $1.77M in Q4 2025. 118 funds tracked by Wall St. Rank hold ADCT as of Q1 2026.

  • Stempoint Capital reported no remaining ADC Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Stempoint Capital sold 502,570 ADC Therapeutics shares in Q1 2026, an estimated $1.77M.
  • Stempoint Capital first reported a position in ADC Therapeutics in Q2 2025 and held it in 3 quarters.
  • Stempoint Capital's ADC Therapeutics position peaked at $1.77M in Q4 2025.
  • 118 funds tracked by Wall St. Rank held ADC Therapeutics as of Q1 2026.

Based on Stempoint Capital's 13F filing for Q1 2026, filed 15 May 2026.